A Comprehensive Board Review in Hematology and Medical Oncology

—A Virtual Live Streaming Course—

August 19-24, 2024

August 19-23, 2024 Solid Tumor and Malignant Hematology

August 22-24, 2024 Malignant and Benign Hematology





Baylor College of Medicine



Making Cancer History®

A Comprehensive Board Review in Hematology and Medical Oncology — A Virtual Live Streaming Course —

GOAL

The course is a 6-day comprehensive review of current standards and practices in the management of patients with blood disorders and malignancy. The course is designed to enable the participant to effectively prepare for the American Board of Internal Medicine certification and recertification examinations in Hematology and Medical Oncology. Advances in clinical pharmacology, molecular genetics and risk assessment, and radiation oncology will be included.

EDUCATIONAL OBJECTIVES

At the conclusion of this educational activity, participants should be able to:

- Apply knowledge gained to prepare for the hematology and medical oncology subspecialty and recertification examinations in hematology and medical oncology
- Utilize current standards of care for patients with cancer, blood disorders and malignancies
- Demonstrate proficiency of knowledge in hematology and medical oncology
- Incorporate recent advances in management of hematologic and oncologic patients; and
- Define molecular determinants of cancer risk and apply this knowledge in practice.

TARGET AUDIENCE

This program should be of interest to Physicians, Advanced Practice Providers, APNs, and Nurses.

EDUCATIONAL METHODS

- Lectures/Didactic
- Case-based Question-and-Answer Sessions (in board examination format)
- Virtual Live Streaming Course
- Canvas an online course management system

EVALUATION

An online course evaluation tool will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvement activities, or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics.

ACCREDITATION



In support of improving patient care, The University of Texas MD Anderson Cancer Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education

(ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CREDIT DESIGNATION

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 50.00 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC POINTS

American Board of Internal Medicine

Successful completion of this CE activity, which includes participation in the evaluation component, enables the participant to earn up to 50.00 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CE credits claimed for the activity.

It is the CE activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points. In order to receive MOC points, you must pass the post-test with a score of 70% or higher.

CE CERTIFICATES AND ATTENDANCE VERIFICATION CERTIFICATES

Certificates awarding AMA PRA Category 1 Credit[™] or certificates documenting attendance will be available to participants once they complete the on-line evaluation. To obtain a CE certificate, physicians must complete the on-line evaluation questionnaire.

A record of attendance (certificate) will be available online to other health care professionals for requesting credits in accordance with state nursing boards, specialty societies, or other professional associations.

PLANNING COMMITTEE MD Anderson Cancer Center

Sharon Giordano, MD, MPH, Co-Director Tapan Kadia, MD, Co-Director Shreyaskumar Patel, MD

Baylor College of Medicine *Martha Mims, MD, PhD, Co-Director* Alessandra Ferrajoli, MD Nishin Bhadkamkar, MD Felisha Estelle

AGENDA

Monday, August 19, 2024

All time is Central Daylight Time (CDT)7 a.m.Virtual Online Registration Check-in

SOLID TUMOR SESSION

5:25 p.m.

Adjourn

Genitourinary Oncology | Melanoma

Genitourinary Uncology Melanoma		
7:30 a.m.	Testicular Cancer Timothy Gilligan, MD	
8:30 a.m.	Urothelial Cancer Arlene Siefker-Radtke, MD	
9:15 a.m.	Renal Cell Carcinoma Eric Jonasch, MD	
10 a.m.	Break	
10:15 a.m.	Prostate Cancer Brad Carthon, MD	
11:15 a.m.	Melanoma Rodabe Amaria, MD	
12 p.m.	Q & A Panel Discussion Timothy Gilligan, MD; Arlene Siefker-Radtke, MD; Eric Jonasch, MD; Brad Carthon, MD; and Rodabe Amaria, MD	
12:15 p.m.	Lunch Break	
Gastrointe	estinal Oncology	
12:45 p.m.	Pancreaticobiliary Cancers/Unknown Primary Robert Wolff, MD	
1:45 p.m.	Gastroesophageal Cancers/Hepatocellular Carcinoma Harry Yoon, MD	
2:45 p.m.	Break	
3 p.m.	Colorectal Cancer: Biology and Adjuvant Therapy Scott Kopetz, MD, PhD	
3:30 p.m.	Metastatic Colorectal Cancer and Anal Cancer A. Koneti Rao, MD, FACP	
4:30 p.m.	Q & A Panel Discussion Robert Wolff, MD; Harry Yoon, MD; Scott Kopetz, MD, PhD; and A. Koneti Rao, MD, FACP	
4:45 p.m.	Solid Tumor Q & A - Session 1: Genitourinary Oncology/Gastrointestinal Oncology/ Melanoma Megan Dupuis, MD	



Tuesday, August 20, 2024

All time is Central Daylight Time (CDT)		
7 a.m.	Virtual Online Registration Check-in	
Pharmaco	logy Genetic Risk Factors Sarcoma	
7:30 a.m.	Pharmacology I: Chemotherapy Claire Mach, PharmD	
8:30 a.m.	Pharmacology II: Targeted Therapy (AIk, EGFR, VEGR, HER2, HH, mTOR) Whitney Lewis, PharmD	
9 a.m.	Break	
9:10 a.m.	Pharmacology III: Targeted Therapy (CD20, CD30, CD33, Proteasome, BCR-ABL/KIT, FLT3, IDH1/2, CDK4/6, PI3K Brian Primeaux, PharmD	
9:40 a.m.	Pharmacology IV: Immunotherapy Claire Mach, PharmD	
10 a.m.	Break	
10:15 a.m.	Genetic Risk Factors Claudine Isaacs, MD	
11 a.m.	Sarcoma Shreyaskumar Patel, MD	
12 p.m.	Q & A Panel Discussion Claire Mach, PharmD; Whitney Lewis, PharmD; Brian Primeaux, PharmD; Claudine Isaacs, MD; and Shreyaskumar Patel, MD	
12:15 p.m.	Lunch Break	
Breast Car	ncer	
12:45 p.m.	Screening/Local Management of Breast Cancer Abenaa Brewster, MD	
1:30 p.m.	Systemic Treatment of Primary Breast Cancer Including HER2 Positive Breast Disease Sharon Giordano, MD	
2:30 p.m.	Break	
2:45 p.m.	Treatment of Metastatic Breast Cancer Including HER2 Positive Breast Disease Mariana Chavez MacGregor, MD	
3:45 p.m.	Special Issues in Breast Cancer Jennifer Litton, MD	
4:15 p.m.	Q & A Panel Discussion Abenaa Brewster, MD; Sharon Giordano, MD; Mariana Chavez MacGregor, MD; and Jennifer Litton, MD	
4:30 p.m.	Solid Tumor Q & A – Session 2: Pharmacology/ Genetic Risk Factors/Sarcoma/ Breast Cancer Mark Lewis, MD	
5:10 p.m.	Adjourn	

Wednesday, August 21, 2024

All time is Central Daylight Time (CDT)		
7 a.m.	Virtual Online Registration Check-in	
Lung Canc	er Head and Neck Cancer Thyroid Cance	
7:30 a.m.	Early Stage and Locally Advanced Non-Small Cell Lung Cancer Nasser Hanna, MD	
8:15 a.m.	Metastatic Non-Small Cell Lung Cancer Nasser Hanna, MD	
9:15 a.m.	Small Cell Lung Cancer Carl Gay, MD	
9:45 a.m.	Break	
10 a.m.	Head and Neck Cancer William N. William, Jr., MD	
10:45 a.m.	Thyroid Cancer Mimi Hu, MD	
11:15 a.m.	Q & A Panel Discussion Nasser Hanna, MD; Carl Gay, MD; William N. William, Jr., MD; and Mimi Hu, MD	
11:30 a.m.	ASH/ASCO Choosing Wisely Recommendations Ravin Garg, MD	
12:10 p.m.	Lunch Break	

Neuro-Onc | Gynecologic Oncology

1 p.m.	Neuro-Oncology Antonio Omuro, MD
1:45 p.m.	Cervical Cancer Alejandro Rauh Hain, MD
2:30 p.m.	Break
2:45 p.m.	Uterine Cancer TBD
3:15 p.m.	Ovarian Cancer and Unusual Ovarian Histologies TBD
4:15 p.m.	Q & A Panel Discussion Antonio Omuro, MD; and Alejandro Rauh Hain, MD
4:30 p.m.	Solid Tumor Q & A – Session 3: Lung Cancer/ Head Neck Cancer/Thyroid Cancer/ Neuro-Onc/Gynecologic Oncology Ravin Garg, MD
5:10 p.m.	Adjourn

Thursday, August 22, 2024

All time is Central Daylight Time (CDT) 7 a.m. Virtual On-line Registration Check-in

MALIGNANT HEMATOLOGY SESSION

Lymphoma | Myeloma

3:15 p.m.

3:30 p.m.

4:15 p.m.

4:30 p.m.

5:10 p.m.

Break

1 7		
Classification of Lymphoma Jeffrey Medeiros, MD		
Aggressive Non-Hodgkin Lymphoma Christopher Flowers, MD		
Indolent Non-Hodgkin Lymphoma Carla Casulo, MD		
Break		
Hodgkin Lymphoma Alison Moskowitz, MD		
Multiple Myeloma and Other Plasma Cell Dyscrasias S. Vincent Rajkumar, MD, PhD		
Q & A Panel Discussion Jeffrey Medeiros, MD; Christopher Flowers, MD; Carla Casulo, MD; Alison Moskowitz, MD; and S. Vincent Rajkumar, MD, PhD		
Lunch Break		
Leukemia MDS		
Chronic Myeloid Leukemia Jorge Cortes, MD		
Myelodysplastic Syndrome Tapan Kadia, MD		
Infectious Complications in Cancer Patients Samuel Shelburne, MD, PhD		

Acute Lymphoblastic Leukemia

Jorge Cortes, MD; Tapan Kadia, MD;

Malignant Hematology Q & A Session

Samuel Shelburne, MD, PhD; and Hagop Kantarjian, MD

Hagop Kantarjian, MD

Patrick Reville, MD

Adjourn

Q & A Panel Discussion

Friday, August 23, 2024

All time is Central Daylight Time (CDT)	
7 a.m.	Virtual Online Registration Check-in

CLL | MPN | Leukemia | SCT

7:30 a.m.	Chronic Lymphocytic Leukemia and Hairy Cell Leukemia Susan O'Brien, MD
8:15 a.m.	Myeloproliferative Neoplasms Raajit Rampal, MD
9:15 a.m.	Break
10 a.m.	Acute Myeloid Leukemia Courtney DiNardo, MD
11 a.m.	Stem Cell Transplant Supportive Care Betty Hamilton, MD
12 p.m.	Q & A Panel Discussion Susan O'Brien, MD; Raajit Rampal, MD; Courtney DiNardo, MD; and Betty Hamilton, MI

12:15 p.m. Lunch Break

BENIGN HEMATOLOGY SESSION

General Topics | Red Cell Disorders | Platelets

1 p.m.	Iron Deficiency and Hemochromatosis Matthew Heeney, MD
1:45 p.m.	Hematopoietic Growth Factors Martha Mims, MD, PhD
2:30 p.m.	Bone Marrow Failure Timothy Olson, MD, PhD
3:15 p.m.	Break
3:30 p.m.	Leukopenia and Leukocytosis Nancy Berliner, MD
4:15 p.m.	Hemolytic Anemias Gerald Soff, MD
5:15 p.m.	Q & A Panel Discussion Matthew Heeney, MD; Martha Mims, MD, PhD; Timothy Olson, MD, PhD; Nancy Berliner, MD; and Gerald Soff, MD
5:30 p.m.	Adiourn

Saturday, August 24, 2024

All time is Central Daylight Time (CDT)		
7 a.m.	Virtual On-line Registration Check-in	
Coagulation Platelets Red Cell Disorders		
7:30 a.m.	Sickle Cell Anemias, Thalassemia, and Hemoglobinopathies Alice Ma, MD	
8:15 a.m.	Issues in Transfusion Medicine Kerry O'Brien, MD	
9 a.m.	Approach to Anemia Alice Ma, MD	
9:30 a.m.	Break	
9:45 a.m.	Disorders of Platelet Function A. Koneti Rao, MD, FACP	
10:30 a.m.	Thrombocytopenias Alfred Lee, MD	
11:15 a.m.	Q & A Panel Discussion Alice Ma, MD; Kerry O'Brien, MD; A. Koneti Rao, MD, FACP; and Alfred Lee, MD	
11:30 a.m.	Lunch Break	

Platelet | Red Cell Disorders | Transfusion Medicine

12:15 p.m.	Benign Heme Q & A Session Senthil Sukumar, MD
1 p.m.	Antithrombotic & Antiplatelet Therapy Bethany Samuelson, MD
1:45 p.m.	Normal Coagulation Kenneth Bauer, MD
2:30 p.m.	Break
2:45 p.m.	Coagulation Factor Deficiencies, Including von Willebrand's Disease and Hemophilias Kenneth Bauer, MD
3:30 p.m.	Hypercoagulable States Stephan Moll, MD
4:15 p.m.	Q & A Panel Discussion Senthil Sukumar, MD; Bethany Samuelson, MD; Kenneth Bauer, MD; and Stephan Moll, MD
4:30 p.m.	Adjourn

Guest Faculty

Bethany Samuelson Bannow, MD, MCR Oregon Health & Science University Portland, Oregon

Kenneth Bauer, MD Beth Israel Deaconess Medical Center Boston, Massachusetts

Nancy Berliner, MD Brigham and Women's Hospital Boston, Massachusetts

Bradley Carthon, MD, PhD Emory Healthcare Atlanta, Georgia

Carla Casulo, MD James P. Wilmot Cancer Institute University of Rochester Rochester, New York

Jorge Cortes, MD Georgia Cancer Center Augusta, Atlanta

Megan Dupuis, MD Vanderbilt-Ingram Cancer Center Lebanon, Tennessee

Ravin Garg, MD Johns Hopkins University Maryland Oncology Hematology -Annapolis Division Annapolis, Maryland

Timothy Gilligan, MD Cleveland Clinic Cleveland, Ohio

Betty Hamilton, MD Cleveland Clinic Cleveland, Ohio

Nasser Hanna, MD Indiana University School of Medicine Indianapolis, Indiana

Matthew Heeney, MD Dana-Farber/Boston Children's Cancer and Blood Disorders Center Boston, Massachusetts

Claudine Isaacs, MD Georgetown University Washington, District of Columbia

Alfred Lee, MD, PhD Yale School of Medicine New Haven, Connecticut **Mark Lewis, MD** Intermountain Healthcare Murray, Utah

Alice Ma, MD University of North Carolina -Chapel Hill School of Medicine Chapel Hill, North Carolina

Stephan Moll, MD University of North Carolina School of Medicine Chapel Hill, North Carolina

Alison Moskowitz, MD Memorial Sloan Kettering Cancer Center New York, New York

Kerry O'Brien, MD Beth Israel Deaconess Medical Center Boston, Massachusetts

Susan O'Brien, MD University of California, Irvine Irvine, California

Timothy Olson, MD, PhD Children's Hospital of Philadelphia Philadelphia, Pennsylvania

Antonio Omuro, MD Yale Cancer Center New Haven, Connecticut

S. Vincent Rajkumar, MD Mayo Clinic – Minnesota Rochester, Minnesota

Raajit Rampal, MD, PhD Memorial Sloan Kettering Cancer Center New York, New York

A. Koneti Rao, MD, FACP Lewis Katz School of Medicine at Temple University Philadelphia, Pennsylvania

Gerald Soff, MD University of Miami Health System/ Sylvester Comprehensive Cancer Center Miami, Florida

William William, Jr., MD BP Hospital Sao Paulo, Brazil

Harry Yoon, MD Mayo Clinic – Minnesota Rochester, Minnesota

REGISTRATION INFORMATION *A Virtual Live Streaming Course*

The Comprehensive Board Review in Hematology and Medical Oncology will be virtual. This program will be presented only as a live streaming course. You will receive an email from the course platform to log in and access the live course online approximately 3 days before the conference.

PRESENTATIONS:

The presentations will be pre-recorded. The speakers will be available for the live Q&A sessions. Course syllabus will not be printed. Presentations (slides) will be available online via the course platform and Canvas. The PowerPoint presentations will be posted online as PDFs prior to the conference. You will receive an invitation email with directives to log in Canvas after the conference adjourns.

- The Full Conference and Oncology Session will begin at 7:30 a.m. on Monday, August 19. The Oncology Session will adjourn at 12:15 p.m. on Friday, August 23, 2024.
- The Hematology Session will begin at 7:30 a.m. on Thursday, August 22 and adjourn at 4:30 p.m. on Saturday, August 24.

Advanced registration is encouraged. Please see the online registration fees page.

*NOTE: The conference registration fee includes the tuition, access to course virtual platform with PDFs of the slides and Canvas - online web-based system with recorded videos.

The deadline for advanced registration is Monday, August 5, 2024.

• Register online at https://mdanderson.cloud-cme.com/HMOBR2024

Telephone registrations are not accepted.

We accept the following forms of payment:

- Credit Cards (MasterCard, VISA, and American Express)
- Check (payable through U.S. banks only)
- Mail to: Continuing Professional Education Unit 1781 The University of Texas MD Anderson Cancer Center P.O. Box 301407 Houston, TX 77230-1407

When registering online a receipt (confirmation letter) will be automatically emailed to the e-mail address you list on the registration form.

REFUND/CANCELLATION POLICY

The registration fee, minus a \$50 administrative handling fee, is refundable if a written request is received on or before **Monday**, **August 5, 2024.** No refunds will be granted after that date. The request for a registration refund must include the tax identification number of the company or institution if registration was paid by a company or institution check. For additional information, contact Continuing Professional Education at 713-792-2223 or toll free at 866-849-5866. Continuing Professional Education reserves the right to cancel activities prior to the scheduled date, if low enrollment or other circumstances make it necessary. Each registrant will be notified by mail, e-mail, or at the phone or fax numbers given on the registration form.

In case of activity cancellation, the liability of Continuing Professional Education is limited to the registration fee. Continuing Professional Education will refund the full registration fee.

Continuing Professional Education reserves the right to limit the number of participants in a program and is not responsible for any expenses incurred by an individual whose registration is not confirmed and for whom space is not available. Please check the website.

PAST CONFERENCES -REVIEWS AND TESTIMONIALS

"The conference was well worth my time. It is nice to be able to take in as much information as possible and have the option of talking to the speakers afterwards. If this board review is still around in ten years (I hope it is), I will certainly attend it again as I study for my recertification."

"Fantastic course! It helped pass my boards with flying colors!"

"As a first time attendee and visitor to MD Anderson, the overall organization and quality of activity was very impressive and met every expectation. Would recommend this activity to any colleague/associate."

> "Excellent review course. The conference was well organized and ran smoothly."

> "Exceeded expectations; worth every penny."

"Superb conference. Exceptional, impressive"

"Very well organized. Amazing how well support staff kept program on time, and fed everyone."

Please let us know what specific topics, issues, or questions you wish to see addressed or emphasized in this activity by emailing Continuing Professional Education at <u>ContinuingEducation@mdanderson.org</u>. All responses will be forwarded to the Course Directors for consideration.

SPECIAL ASSISTANCE

Contact Felisha Estelle in Continuing Professional Education at 713-745-0083 or 1-866-531-MOBR (6627) if you have any ADA accommodation needs.

CONFERENCE REGISTRATION - D128821

Comprehensive Board Review in Hematology

and Medical Oncology

August 19-24, 2024

CONFERENCE REGISTRATION FEES

Full Conference - MDs, PhDs, DOs, PharmDs

Postmarked on or before July 22, 2024	. \$1,200
Postmarked on or before August 5, 2024	. \$1,300
Postmarked after August 5, 2024	\$1,400

Full Conference - Residents/Fellows/MD Anderson Alumni*

Postmarked on or before July 22, 2024	\$800
Postmarked on or before August 5, 2024	\$900
Postmarked after August 5, 2024.	\$1,000

Oncology Session - 4 ½ days (Monday - Friday A.M.) MDs, PhDs, DOs, PharmDs

□ Postmarked on or before July 22, 2024	\$650
Postmarked on or before August 5, 2024	\$700
Postmarked after August 5, 2024	\$750

Oncology Session - 4 ½ days (Monday - Friday A.M.) Residents/Fellows/MD Anderson Alumni*

Postmarked on or before July 22, 2024	\$450
Postmarked on or before August 5, 2024	\$500
Postmarked after August 5, 2024.	\$550

Hematology Session - 3 days (Thursday - Saturday) MDs, PhDs, DOs, PharmDs

Postmarked on or before July 22, 2024	\$550
Postmarked on or before August 5, 2024	\$600
Postmarked After August 5, 2024	\$650

Hematology Session - 3 days (Thursday - Saturday)

Residents/Fellows/MD Anderson Alumni*

Postmarked On Or Before July 22, 2024							\$350		
🗖 Postma	arked ()n Oi	r Bef	ore A	ugust	5, 2024 .	 	 	\$400
🗖 Postma	arked a	fter	Aug	ust 5,	2024		 	 	\$450
							 	 ~	

Advanced Practice Providers/Nurses/Advanced Practice Nurses"	\$450
MD Anderson/Baylor Faculty/Staff	\$500
MD Anderson/Baylor Clinical Fellows*Exe	ampt

*A letter of introduction from the program director or chairperson with registration form is required to claim this reduced fee.

Make check payble to:

The University of Texas MD Anderson Cancer Center

2024 HEMATOLOGY AND MEDICAL ONCOLOGY BOARD REVIEW: COMPREHENSIVE PROGRAM MATERIAL AVAILABLE FOR NON-ATTENDEES

Comprehensive source material can provide you with home-study material designed for fellows-in-training, physicians planning to take the Hematology or Medical Oncology certifying examination, or physicians wishing to review the established standards of care in Hematology or Medical Oncology.

The conference registration fee includes the tuition, access to the course virtual platform with PDFs of the slides and Canvas (online web-based system with recorded videos).

NOTE: The conference will be available through an online course management system (Canvas) where you will be able to view each recorded lecture. The full conference will be available approximately 12 days after the conference adjourns. Instructions for access to Canvas will be provided.

CE Credits and MOC Points are awarded only by attending the virtual live course. Credits and points can not be awarded for watching the on-demand videos after the course has adjourned.

Available option to obtain course material:

CANVAS - online web-based system with recorded videos (Log in instructions will be provided)

- Online site with downloadable audio & videos for the entire 2024 course
- Each speaker's complete PowerPoint slide presentation (Adobe Acrobat PDF file)
- · Full color, just as presented
- Each speaker's list of references
- Please allow 3-5 business days to process order before receiving log in instructions

D128822/PS118825

NON ATTENDEES

CANVAS - online system with recorded videos.....\$1,000.00

Please note: Flash drives are no longer available to purchase.

Telephone orders are not accepted.

Register online at https://mdanderson.cloud-cme.com/HMOBR2024

ALL SALES ARE FINAL.

Make check or money order payable to: The University of Texas MD Anderson Cancer Center. Please allow 3-5 business days to process order before receiving log in instructions.



The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially affect the information presented.

MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity.

Agendas are subject to change because we are always striving to improve the quality of your educational experience. MD Anderson may substitute faculty with comparable expertise on rare occasions necessitated by illness, scheduling conflicts, and so forth.

Photographing, audio taping and videotaping are prohibited.

The University of Texas MD Anderson Cancer Center Continuing Professional Education - Unit 1781 176700/30/128821/41 P.O. Box 301407 Houston, Texas 77230-1407

Non-Profit Org. U.S. Postage P A I D Houston, TX Permit No. 7052